Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions highlighted the vaccine's promise, particularly noting that over 90% of participants showed positive antibody responses following the first dose. Phrases like 'very promising results' and 'game changer' reflect a tone of optimism and urgency, showcasing the perceived significance of the findings. Some users expressed skepticism regarding misinformation about vaccines, using strong language to argue their points, reinforcing the publication's critical role in addressing vaccine-related concerns.
Many discussions show supportive views on the safety and effectiveness of the vaccine, although a few skeptical voices were present.
The volume of posts indicates a strong curiosity about the vaccine's trial results and implications.
While many users shared opinions, there were also references to scientific data and trial results that demonstrated a moderate level of engagement.
Users frequently discussed the potential for significant public health benefits from the vaccine, indicating a belief in its importance.
Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as good as Johnson and Johnson. https://t.co/KiKhMRnHEi https://t.co/91yMFh7Ido https://t.co/3AJGlzzJkG
The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies but with a delayed rise at 2-3 months, so by calling the study sooner you tend to bias against seeing the best effect https://t.co/XRo6LHAVSP
Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of participants made neutralizing antibody titers & most showed strong T cell responses. Data from phase 3 trial expected in next few weeks. https://t.co/D5thwkjB5U
And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity being measured at 90%! Very high. Maybe one dose will work for mass control & phase 3 trial soon! https://t.co/en8Swcdm5E https://t.co/U9uEJxCgj6
to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/II trial showed increasing antibodies and T cell responses over time: kept on going up past 2 weeks out to 59 days when stopped looking https://t.co/RHLOe6leWZ
Na sowas… ich habe Frau Schepis auf Twitter zwar nie kontaktiert, aber sie kann mich irgendwie nicht leiden… denkt ihr, dass dieses Video etwas damit zu tun haben könnte? Debunked: Kati Schepis - Die Mutter aller „Querdenker“ (Schweiz) https://t.co/y0FppjotGH https://t.co/ycc4rMXYam
Frau Kati Schepis presents a lecture at the ALETHEIAMediakonferenz in Switzerland. She summarizes known COVID-19 myths and introduces new falsehoods. The video details the inaccuracies in her claims, comparing them…
This video reviews the primary COVID-19 vaccines approved by EMA, including Pfizer-BioNTech, Moderna, AstraZeneca, Johnson & Johnson, and others like Novavax, Sputnik V, Sinovac, and Sinopharm, highlighting their…
In this video I break down the scientific literature on the Johnson Johnson COVID19 vaccines in a simple way for all to understand. The vaccine uses a replication-incompetent Ad26 viral vector, delivering transgenes…
@KBr_enthusiast @minagelina1 @DrBenTapper1 Can't trust the internet. Try this: https://t.co/bXalPISVKy
RT @Unheilpraktiker: @Sven__Weiss @ZweitAcccount @MarkelGerald https://t.co/4dee8bwBd8 https://t.co/4dee8bwBd8 https://t.co/0Ip3PtDnCe h…
@Sven__Weiss @ZweitAcccount @MarkelGerald https://t.co/4dee8bwBd8 https://t.co/4dee8bwBd8 https://t.co/0Ip3PtDnCe https://t.co/QfJiSsRGEo https://t.co/rIYWbUTzvw https://t.co/CIVIPmaI0a
@canadasgoose Keep burying yourself. There were many. https://t.co/q9npMbbdyW
@kati_schepis @SchneidGabriel Ach Frau Kati Schepis. Wir wissen genau, dass sie eine Lügnerin sind. Sie haben wärend Corona öffentlich lügen erzählt! https://t.co/W8XmonOUjV
@kirakirstynkira @JesslovesMJK And if you really care, here's Novavax: https://t.co/2HTHoVUfdm Sinovac: https://t.co/f4XMZfLs0p J&J: https://t.co/qK0TVlv158 Astrazeneca: https://t.co/lDDrkNKJLL
@Ze1002Co @FrauPanda_ @BrinkmannLab @DrHegedues Oh man… das ist nun wirklich ein ganz ganz alter Schuh! NEIN! Die Impfung führt NICHT zu Problemen! Bitte machen sie sich nicht lächerlich! https://t.co/LXricrmg3o
@StandPunkt_News ...wird Philipp Kruse und Kati Schepis auch da sein? Würde mich freuen! ... ... ... https://t.co/8yoqGqvhf2
@SigurdW3 @kati_schepis Bist du ernsthaft so blöd?! LongCovid gab es schon, bevor die Impfung auf dem Markt war! Kati Schepis ist eine Lügnerin! https://t.co/LXricrmg3o
@fluri_f @kati_schepis Ernsthaft?
RT @DrHegedues: Na sowas… ich habe Frau Schepis auf Twitter zwar nie kontaktiert, aber sie kann mich irgendwie nicht leiden… denkt ihr, das…
RT @DrHegedues: Na sowas… ich habe Frau Schepis auf Twitter zwar nie kontaktiert, aber sie kann mich irgendwie nicht leiden… denkt ihr, das…
RT @SimonFrei8: @kati_schepis gibt es eigentlich eine Reaktion Ihrerseits auf die Kritik von Janos? ....gemeint ist eine sachlich fachlich…
Na sowas… ich habe Frau Schepis auf Twitter zwar nie kontaktiert, aber sie kann mich irgendwie nicht leiden… denkt ihr, dass dieses Video etwas damit zu tun haben könnte? Debunked: Kati Schepis - Die Mutter aller „Querdenker“ (Schweiz) https://t.co/y0FppjotGH https://t.co/ycc4rMXYam
@kati_schepis gibt es eigentlich eine Reaktion Ihrerseits auf die Kritik von Janos? ....gemeint ist eine sachlich fachliche auf den Inhalt bezogen. https://t.co/joAykS1tjE
@Tom_Rumi @FabianMolinaNR Kati Schepis, man haben wir gelacht.
@ImPeriuS7777 @VorsitzenderNAV https://t.co/LXricrmNSW
@HNohynek @THLorg Vaiheen 1/2 tutkimuksissa annettu KAKSINkertainen Janssen‑rokoteannos siedettiin hyvin: https://t.co/JDfrrhgTxD After the 2nd dose incidence of adverse events was much lower than that after the 1st immunization in low & HIGH-dose groups: https://t.co/x9h18s4L7l -
RT @fourthdose: @HNohynek @THLorg Haen tehosteen ulkomailta 2kk välein. Suomessa ei saa ostettua yksityiseltä. Tanskasta voi ostaa Janssen.…
@HNohynek @THLorg Haen tehosteen ulkomailta 2kk välein. Suomessa ei saa ostettua yksityiseltä. Tanskasta voi ostaa Janssen. https://t.co/wrGPSN0SSY 3. annoksena Janssen on Pfizeriä tehokkaampi: https://t.co/CQsQ901lQS High-dose Janssen on tehokkaampi kuin normaali Janssen: https://t.co/x9h18s4L7l https://t.co/olVCwXOOID
@mpc_xetts @HeyNowTrucker "Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine"
@mpc_xetts @HeyNowTrucker by the way here's phase 1 in 2021. https://t.co/o6AlogNJiw
@darby_crashed Here's just one of many with numbers ;) data https://t.co/eRJyvu2uCc
@RnEmergency J & J Ph 1-2 results https://t.co/ZICQZI6F7w Ph 3 results https://t.co/8KXN6rDIyV
@Rdi22591682 @reitschuster https://t.co/5ItBBGPf0x
@ForeverRJYoung @GinaPhi94724925 https://t.co/dfmSaBlNXU
@SvenKrause68 @Hirn_aus_Hack @holmenkollin Sie schauen doch so gerne Videos an. Hier zu den Nebenwirkungen https://t.co/xZEb1rpmfT
@Kachelmann Noch etwas krasser diese Schweizer "Expertin", deren Quatsch im Netz die Runde machte.
@Ronny0971 Sie verbreiten medizinische Falschaussagen. Siehe hier: https://t.co/n06bfQdsgk Wie gesagt, das hat Folgen. In Pandemiezeiten sind die u.U. fatal. Wenn Sie selber von etwas nichts verstehen (Probanten[sic!] - das sind die Testpersonen!!!) dann sprechen Sie bitte nicht darüber.
@Ronny0971 Und kompletten Schrott erzählt. https://t.co/n06bfQdsgk
RT @NGegenrechts: Dr. #Hegedüs über Desinformation auf einer Schweizer Schwurbelkonferenz: "Debunked: Kati Schepis - Die Mutter aller „Quer…
Dr. #Hegedüs über Desinformation auf einer Schweizer Schwurbelkonferenz: "Debunked: Kati Schepis - Die Mutter aller „Querdenker“ (Schweiz)" https://t.co/KwJ0OZsAa1 via @YouTube
Aufklärung über die sogenannte Querdenker:innen- hier sehr gut aufbereitet von Dr. Hegedüs- siehe Video unten... https://t.co/6xmXyjKg0U
RT @martin_koradi: Janos Hegedüs demontiert Punikt für Punkt das Desinformationspaket der Corona-Leugner. #impfenstattschimpfen @JaKampagn…
RE: Kati Schepis - Aletheia Medienkonferenz (Schweiz) https://t.co/eeKSiFX9pB via @YouTube
@WolfvanderMaske @Karl_Lauterbach @ChristinaBerndt https://t.co/XiRZYc23vm
Janos Hegedüs demontiert Punikt für Punkt das Desinformationspaket der Corona-Leugner. #impfenstattschimpfen @JaKampagne @freiheitsimpfin Kati Schepis - Aletheia Medienkonferenz (Schweiz) https://t.co/88MIoaUkjC via @YouTube
Das ist Mal Aufklärung zu Impfung besser geht nicht https://t.co/N3qqlUJPe9
@TshintshaNuName Last year from Nov to this year Jan/Feb. 1. J&J: https://t.co/JDEbY67MLX 2. Pfizer: https://t.co/SxsCIeS97Y
@RandPaul https://t.co/iHMwH8uQHQ
@edenjade28 @AtlanciaZA @A_C_D_P @LoaGong https://t.co/3eRXMDc6Wa
@edenjade28 @AtlanciaZA @A_C_D_P @LoaGong P2 data for the J&J vaccine https://t.co/3eRXMDc6Wa
@brian_brianr @LindaGailBekker The J&J Ensemble 2 trial showed success of a 2 dose approach. https://t.co/TpRgnXFttx That doesn't mean that another vaccine wouldn't be better.
@doobybutts @MorbiusMovies @voelterrificart @Timcast Here's the phase 3 study: https://t.co/fzouEa9dTM Here's more: https://t.co/8C0INosafH https://t.co/gihrTx5dLI https://t.co/5d880paRCv
RT @michaelzlin: I showed results for older adults as they need protection from infections the most, but younger adults showed the same tre…
@dseLIVEtrader (3/3) than the two shot mRNA vaccines. https://t.co/ZWRx7or7qJ (prelim reuslts with antibody levels not net efficacy which has not yet pulbished. The company claims 100% against severe illness, 94% against symptomatic). FDA has approved mix and match. https://t.co/Hlg0ovPdAS
@YaserMahmoudi5 @A_hosein_A @amirjoulaei @samanebidel 4: https://t.co/qUAben1HIw https://t.co/rLeIJSlSpq
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
RT @PeterHotez: The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies…
The original phase 1-2 studies published in @nejm were very promising with 2 doses giving very high neutralizing antibodies but with a delayed rise at 2-3 months, so by calling the study sooner you tend to bias against seeing the best effect https://t.co/XRo6LHAVSP
RT @michaelzlin: I showed results for older adults as they need protection from infections the most, but younger adults showed the same tre…
RT @michaelzlin: I showed results for older adults as they need protection from infections the most, but younger adults showed the same tre…
I showed results for older adults as they need protection from infections the most, but younger adults showed the same trend (with higher abs in each case). You can look yourself at https://t.co/EwQkn2MSMW https://t.co/leuqT1lzZ2 https://t.co/IqEX4IHU2l https://t.co/HWhslODxZX
Today's PR says the 2nd shot at 2mo (in ENSEMBLE2) boosted Ab levels 4-6x. That's good, and in line with Phase 1-2 results where shot2 was found to increase antibody levels by 3x. https://t.co/8vgDusQCtP https://t.co/h4ueCfJQp5
@RnInfection @MichaelDaignau3 @real_faox @sailorrooscout I think this is about the limit of it
所有受批准的新冠疫苗，无论是辉瑞、莫德纳还是强生疫苗，都是安全、有效的，并会对你提供保护。 https://t.co/3Ovl0Aogwc, https://t.co/EBt9MPUpUS #coronavirus #covid19 #corona #virus #quarantine #socialdistancing #pandemic #graphic #health #publichealth #chinese #letschat #uwchat https://t.co/lxZVfXVcxH
Toda las vacunas de COVID-19 aprovadas - ya sea Pfizer, Moderna, o Johnson&Johnson - son seguras, efectivas, y brindaran proteccion. https://t.co/3Ovl0Aogwc, https://t.co/EBt9MPUpUS https://t.co/KYktYXbXKz
All approved COVID-19 vaccines - whether its the Pfizer, Moderna, or Johnson&Johnson vaccine - are safe, effective, and will provide protection. https://t.co/3Ovl0Aogwc, https://t.co/EBt9MPUpUS https://t.co/CEdah7JgJ7
On this point, note we did see a set of antibody and T cell results from their Phase 2 two-dose trial, where there was a 2.6- to 2.9-fold jump in antibodies after the second dose, 1 month after the first. https://t.co/8vgDusQCtP
RT @carpe_diem0820: J&Jが開発する新型コロナワクチンの第Ⅰ/Ⅱ相臨床試験結果 中和抗体価は初回接種29日後に90％以上で検出 57日目に100％に到達 抗体力価は少なくとも71日目まで安定 2回目の接種で2.6～2.9倍力価が上昇 Interim Resu…
@SpechtNicki @citizen_crystal @bearded_ninny https://t.co/HVa1R6Jyra
@citizen_crystal @bearded_ninny @SpechtNicki First .. never take the companies press releases for fact. Try the real study . Trial started in July 2020. Click the tabs for methods , results etc. . Explore. https://t.co/HVa1R6Jyra
@Eugene42387473 @10e_b @NOS Grappig dat er tot nu toe bijna nul studieresultaten zijn, op een enkele daargelaten. Maar he geloof me niet joh, hoeft niet, hoop dat je van lezen houdt. En heb ik gezegd dat Corona een complot is.. Nope. https://t.co/66xB1hZOz9
No clinical data with the Ad26COVS1 vaccine are currently available as this will be the first-in-human study.: Approved for Dossier Use, Date: 20 April 2020/pag.46. . The effect of the study vaccine on a foetus or on nursing baby is unknown / pag.49 https://t.co/66xB1hZOz9
@DrLeanaWen @PostOpinions This is the J&J phase 2a study from May 2021 and it mentions data was being collected for 2 doses of J&J vaccine. Was that data ever published? https://t.co/V2sefr1mwl
@mfg_sylwia_k_b @KaiMeinecke @Karl_Lauterbach Laut https://t.co/WDo1rRjqKI hat J&J zunächst die Zulassung mit 1 Dosis beantragt und parallel eine Studie über 2 Dosen gestartet. Hier das Zwischenergebnis dieser Studie: https://t.co/BHv1lxyqTT Offiziell läuft die noch, aber die Ergebnisse sprechen anscheinend nicht dafür.
@PercyMaltese @CraigARobinson @ianfmusgrave @BioinfoTools @jonfarquhar1 @pohutukawa @TinFoilAwards @okay2disagree @Pro_Libertatis @handmadekathy @mcfunny https://t.co/yBViGzcXQt
If anyone tells you they are researching COVID-19 vaccines. The actual Clinical trials are a good place to start. Moderna Vaccine Clinical Trial https://t.co/hJb8FkCb0Q Pfizer Vaccine Clinical Trial https://t.co/snWlqqeZOf J&J Vaccine Clinical Trial https://t.co/Doo6lD3dRO
@Vicyclist If anyone tells you they are researching COVID-19 vaccines. The actual Clinical trials are a good place to start. Moderna Vaccine Clinical Trial https://t.co/hJb8FkCb0Q Pfizer Vaccine Clinical Trial https://t.co/snWlqqeZOf J&J Vaccine Clinical Trial https://t.co/Doo6lD3dRO
@Runaways1983 @andylancaster @FilosoferzBLike Would be unsure about safety there. 56-day interdose interval was used in the J&J Phase 2 trial: https://t.co/8vgDusQCtP You should consult your doctor if you're interested in a boosters regardless. I can provide only a scientific evaluation of the studies.
@picazzolive @Coll1313 @ScottAdamsSays India is off the news because of the focus on US cases. Also, here are some studies: https://t.co/ImU3TTv6Lg https://t.co/tKC9LdbVI7
RT @michaelzlin: The best evidence comes from J&J themselves, who tested 2 vs 1 dose, and found 2 doses to produce ~3x more antibodies in t…
The best evidence comes from J&J themselves, who tested 2 vs 1 dose, and found 2 doses to produce ~3x more antibodies in the Phase 2 trial. That's with the known issue of clearance of the second dose by antibodies made against the Ad carrier too. From https://t.co/8vgDusQCtP https://t.co/YJuqf1PPx5
RT @MonicaGandhi9: to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/I…
RT @MonicaGandhi9: to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/I…
@ath33 @MonicaGandhi9 No. It was 400. https://t.co/gr6xVbhLJd
RT @MonicaGandhi9: Remember about J&J which is that - in its phase I/II clinical trial, antibody and CD4/CD8 (T cell) responses increased o…
RT @MonicaGandhi9: Remember about J&J which is that - in its phase I/II clinical trial, antibody and CD4/CD8 (T cell) responses increased o…
RT @MonicaGandhi9: Remember about J&J which is that - in its phase I/II clinical trial, antibody and CD4/CD8 (T cell) responses increased o…
RT @MonicaGandhi9: Remember about J&J which is that - in its phase I/II clinical trial, antibody and CD4/CD8 (T cell) responses increased o…
RT @MonicaGandhi9: Remember about J&J which is that - in its phase I/II clinical trial, antibody and CD4/CD8 (T cell) responses increased o…
Remember about J&J which is that - in its phase I/II clinical trial, antibody and CD4/CD8 (T cell) responses increased over time. Not that high at 2 weeks (which may account for lesser effectiveness in ENSEMBLE trial when looking at that time point) https://t.co/RHLOe6leWZ
@Eric_T1990 @HeidiGiokos The J&J Sisonke trial efficacy was measured against the unvaccinated population.The aims of the trial can be found here. https://t.co/qemA3UdyKY Double blind trials had already been conducted and are reported here https://t.co/qemA3UdyKY
RT @roslemusmartin: ...y las respuestas de las células T a lo largo del tiempo: siguió subiendo durante las últimas 2 semanas hasta los 59…
RT @roslemusmartin: ...y las respuestas de las células T a lo largo del tiempo: siguió subiendo durante las últimas 2 semanas hasta los 59…
RT @roslemusmartin: ...y las respuestas de las células T a lo largo del tiempo: siguió subiendo durante las últimas 2 semanas hasta los 59…
...y las respuestas de las células T a lo largo del tiempo: siguió subiendo durante las últimas 2 semanas hasta los 59 días https://t.co/2G27AWcuFD
RT @MonicaGandhi9: to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/I…
@beto_california @SantiOlsze @diegomartin76ok @norabar La investigación publicada en el New England Journal of Medicine https://t.co/HEGSMTGfyk
RT @MonicaGandhi9: to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/I…
RT @MonicaGandhi9: to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/I…
RT @chayito09: contra la fiebre amarilla). La vacuna J&J es interesante porque una sola dosis en los estudios de fase I/II mostró un aument…
RT @MonicaGandhi9: to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/I…
RT @chayito09: contra la fiebre amarilla). La vacuna J&J es interesante porque una sola dosis en los estudios de fase I/II mostró un aument…
RT @MonicaGandhi9: to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/I…
RT @MonicaGandhi9: to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/I…
contra la fiebre amarilla). La vacuna J&J es interesante porque una sola dosis en los estudios de fase I/II mostró un aumento de los anticuerpos y las respuestas de las células T con el tiempo: siguió aumentando durante las 2 semanas hasta los 59 días https://t.co/d8Zy7MbMXH 5/
RT @MonicaGandhi9: to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/I…
to get strong response and some need 1 dose (like yellow fever vax). J&J vaccine interesting in that 1 dose in phase I/II trial showed increasing antibodies and T cell responses over time: kept on going up past 2 weeks out to 59 days when stopped looking https://t.co/RHLOe6leWZ
RT @MonicaGandhi9: step "upstream" from mRNA vaccines so gives you DNA which you MAKE into mRNA and then you make spike protein. mRNA vax a…
RT @MonicaGandhi9: step "upstream" from mRNA vaccines so gives you DNA which you MAKE into mRNA and then you make spike protein. mRNA vax a…
RT @MonicaGandhi9: step "upstream" from mRNA vaccines so gives you DNA which you MAKE into mRNA and then you make spike protein. mRNA vax a…
RT @MonicaGandhi9: step "upstream" from mRNA vaccines so gives you DNA which you MAKE into mRNA and then you make spike protein. mRNA vax a…
@BreezeMountains @MarcGoldwein @ATabarrok https://t.co/QKpPhMA1bZ
@WeWontBSilenced @michaelzlin Hopefully Ensemble 2 results comes out soon! This is a link to the Phase 2: https://t.co/4BkMEKoIzW
Un recordatorio de que la vacuna J&J puede tomar hasta 60 días en producir inmunidad contra el SarsCoV2. No 28 días. https://t.co/ZiTXfX8Uch
RT @MonicaGandhi9: step "upstream" from mRNA vaccines so gives you DNA which you MAKE into mRNA and then you make spike protein. mRNA vax a…
@Rschooley @RandilynIsIn I'm in Cohort 3 of a J & J two-shot vaccine study that began in August 2020, with no adverse reaction to either dose. I know I received the vaccine and not a placebo, but not if I received the higher or lower dose. Interim results here: https://t.co/gajk7eIBui
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/faEprVtddz
JJ phase 1-2a interim report placebo controlled, 805 adults https://t.co/rthpUs4c9r
RT @EllaMatamala: @jp0757 @IsisVirginal @yuyuniznavas Tienes miedo porque no sabes. No temas a las vacunas, protégete e infórmate. Tecnolog…
@jp0757 @IsisVirginal @yuyuniznavas Tienes miedo porque no sabes. No temas a las vacunas, protégete e infórmate. Tecnología de vacunas con vectores virales ya de habían aprobado para el ébola. Esta es la información de la fase 1 y 2 y la final de la Jansen. https://t.co/eRm3Hy3DOq https://t.co/7r1A3cmqpW
"Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine" (2021) https://t.co/kklH4RKvdd
RT @WearingisCaring: Our graphic is based on this research paper from @NEJM! #scicomm #science https://t.co/d0CuNtH6yz
RT @WearingisCaring: Our graphic is based on this research paper from @NEJM! #scicomm #science https://t.co/d0CuNtH6yz
Our graphic is based on this research paper from @NEJM! #scicomm #science https://t.co/d0CuNtH6yz
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/PkRCxZwKDn
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. https://t.co/OdJfeXp8k4
2021/5/13 出版分 twitterでバズった論文 全分野 Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/eQy64erxay Tweets: 3981
Covid-19 ワクチン Ad26.COV2.S の第 1・2a 相試験の中間解析結果 https://t.co/L6dodh0hXt Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/JuvvH9Q9ey
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/TJ96NG0DtA
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/MNryc55ubf
Ad26.COV2.Sというと、J&J/Jansenか。 Covid-19 ワクチン Ad26.COV2.S の第 1・2a 相試験の中間解析結果 | The New England Journal of Medicine（日本国内版） https://t.co/P4LRSobl3d Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/By8IeBmOKf
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/xPy0OHF9zA
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
RT @laoneill111: Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as…
Scientific justification for spacing out Pfizer shots: Pfizer one shot versus Johnson and Johnson one shot- Pfizer just as good as Johnson and Johnson. https://t.co/KiKhMRnHEi https://t.co/91yMFh7Ido https://t.co/3AJGlzzJkG
@TheGazmanRants @florian_krammer The information on Janssen is based on Figure 2B of 'Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine' by Sadoff et al. Low dose: 5e10 viral particles, the current dosage High dose: 1e11 viral particles HCS: Human Convalescent Serum https://t.co/MLbMr0KVn9 https://t.co/NPK1GFzpw8
“Neutralizing-ab titers against wt virus were detected in 90% or more of all participants on day 29 after the first vaccine dose ... regardless of vaccine dose or age group”Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine|NEJM https://t.co/cdOIZZsrUY
3) Johnson&Johnson vaccine increases antibodies 1000-fold (Figure 2 at https://t.co/dolknMtoj1): https://t.co/FPI7CNaXzv
https://t.co/gnRdvW1mTt
La vacuna J&J codifica una proteïna S d SARS-CoV-2 d longitud completa i estabilitzada. Conté mutació del lloc d clivatge d la furina i mutacions estabilitzadores de la prolina, a diferència de la AZ. https://t.co/9EerT0oxe1 https://t.co/vEqpxaI9H0 https://t.co/i0ElfGYrHY https://t.co/PfgJ07dsW0
RT @profshanecrotty: 3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substant…
@BogochIsaac Should we be concerned about the risk of "vaccine-associated enhanced respiratory disease" as this study discusses, for the J&J. or Ad26. Word search "enhanced". https://t.co/QbxVENRJFg
#SARSCoV2 #ad26 viral vector against #COVID19 Thanks to @JNJGlobalHealth @PascalPraud https://t.co/h1irZLHG7s
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/ozOY5dFZiN
RT @NGourd: JANSSEN Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/4zlf7hNaPx
ヤンセン・ファーマ（ジョンソン・エンド・ジョンソン）のワクチン候補治験第1-2a相臨床試験結果 NEJM論文 Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/kog3arqKBX
Información (avance "prospecto") sobre la vacuna Johnson & Johnson. - 'The New England Journal of Medicine' (descargar pdf): https://t.co/60zhXyjrCX - Web corporativa: https://t.co/eVCFnrhuHp #VacunaJonhson #VacunasCOVID19 #COVID19
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM. Odlican rezultat. Jos jedna dobra vakcina. https://t.co/QNLO6z2bLT
RT @profshanecrotty: The Rus vaccine saw 8x more neutralizing antibodies after the 2nd shot. J&J got 4x more neutralizing antibodies after…
RT @profshanecrotty: The Rus vaccine saw 8x more neutralizing antibodies after the 2nd shot. J&J got 4x more neutralizing antibodies after…
RT @profshanecrotty: The Rus vaccine saw 8x more neutralizing antibodies after the 2nd shot. J&J got 4x more neutralizing antibodies after…
RT @profshanecrotty: The Rus vaccine saw 8x more neutralizing antibodies after the 2nd shot. J&J got 4x more neutralizing antibodies after…
RT @profshanecrotty: The Rus vaccine saw 8x more neutralizing antibodies after the 2nd shot. J&J got 4x more neutralizing antibodies after…
RT @profshanecrotty: The Rus vaccine saw 8x more neutralizing antibodies after the 2nd shot. J&J got 4x more neutralizing antibodies after…
RT @profshanecrotty: The Rus vaccine saw 8x more neutralizing antibodies after the 2nd shot. J&J got 4x more neutralizing antibodies after…
The Rus vaccine saw 8x more neutralizing antibodies after the 2nd shot. J&J got 4x more neutralizing antibodies after 2-dose compared to 1-dose. So, it is reasonable to expect that the ongoing J&J 2-dose COVID vaccine clinical trial will do quite well. https://t.co/kt3WpOEEfX
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/UXbhs1A8wK
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
RT @ZapateroAntonio: Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con…
Buenos resultados de fase 1 y 2 de la vacuna de @JNJNews, buena inmunidad tanto con dosis altas, dosis más bajas y con dosis única o repetida, que anima a completar fase 3 https://t.co/VZLVrjZnje
@Ryan_Mac_Phd I understand your point, but if immunity induced by the initial dampened responses to a second dose, then how would you explain the increase in neutralizing antibody titers following the second dose of the J&J vaccine reported in their interim results? https://t.co/ooYPWoB7ab
RT @profshanecrotty: 3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substant…
@travelchick321 @newsjunkie1928 @nypost Just an article. Well I guess if you didn't see it on Newsmax or OANN it must definitely be false. Here's a study from the New England Journal of Medicine. Good luck. https://t.co/XVXwTNGtAe
@travelchick321 @newsjunkie1928 @nypost Here's a study from the New England Journal of Medicine. https://t.co/XVXwTNGtAe
RT @profshanecrotty: 3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substant…
RT @profshanecrotty: 3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substant…
And... of course who said J&J would stay a "one jab" item...https://t.co/ULJhL2bjXT, lot's of homework for the "immunological illiterate" https://t.co/jnWBnpJ6tN https://t.co/VSWKi29gAQ
@FireMountainGl1 @c_nov20 Hi- the phase 3 results are just in a press release (paper should be forthcoming). Antibodies measured (and T cells) in the phase I/II trial: https://t.co/en8Swcdm5E
RT @profshanecrotty: 3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substant…
@DianaR41265367 @CarlosA51856874 @NoticiasCaracol en esta publicación dice q a los 57 días de aplicada la dosis el 100% alcanzaron los anticuerpos (algunos antes), las vacunas evitan que nos enfermemos, no necesariamente el contagio y ninguna vacuna ha determinado cuanto tiempo duran los anti-cuerpos https://t.co/9TtKgwINLM
RT @profshanecrotty: 3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substant…
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/JfQMiVPaDC #CovidVaccine
RT @profshanecrotty: 3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substant…
RT @profshanecrotty: 3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substant…
RT @profshanecrotty: 3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substant…
3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substantial boost to the antibody response after a 2nd immunization. A 4x gain. (T cell responses after the 2nd dose were not reported) https://t.co/mSw7AmAgQc
@Summers33456923 @2dedostesta @Public_Citizen @propublica @blowwhistleloud @AOC @SenSanders @ewarren @trayNTP @TheGrayzoneNews @HighWireTalk @BernieSanders @JayChance12 @POTUS @JoeBiden @VP @KamalaHarris @NIH @BarackObama @Baric_Lab @axios @PeterDaszak @EcoHealthNYC @threadreaderapp @Twitter @WhiteHouse Considering the risks involved, even with limitations, Novavax seems to be the safest
RT @MonicaGandhi9: gets the DNA inside host cell nucleus where it is "transcribed" into mRNA and then you make the spike protein of the vir…
gets the DNA inside host cell nucleus where it is "transcribed" into mRNA and then you make the spike protein of the virus % raise immune response against it. Initial phase I/II data from NEJM showed high immunogenicity of 1st dose that went up over time. https://t.co/en8Swcdm5E
RT @1000genes: Nueva vacuna candidata en marcha a los ensayos clínicos: El ensayo de fase 1-2a de la vacuna de Johnson & Johnson (Ad26.C…
RT @1000genes: Nueva vacuna candidata en marcha a los ensayos clínicos: El ensayo de fase 1-2a de la vacuna de Johnson & Johnson (Ad26.C…
RT @1000genes: Nueva vacuna candidata en marcha a los ensayos clínicos: El ensayo de fase 1-2a de la vacuna de Johnson & Johnson (Ad26.C…
RT @1000genes: Nueva vacuna candidata en marcha a los ensayos clínicos: El ensayo de fase 1-2a de la vacuna de Johnson & Johnson (Ad26.C…
Nueva vacuna candidata en marcha a los ensayos clínicos: El ensayo de fase 1-2a de la vacuna de Johnson & Johnson (Ad26.COV2.S) demuestra perfiles de seguridad e inmunogenicidad que apoyan su desarrollo como vacuna frente a COVID-19. https://t.co/nMSC8OzaSD
Summary: This study shows that the @JNJNews vaccine is safe & immunogenic after only 1 dose, which has significant logistical advantages over current 2-dose vaccines. Results from the ongoing phase 3 trial will provide more evidence on dosing and efficacy https://t.co/gIPJVmh0HH
'Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine' https://t.co/1qriTPSZG4
@hfliester @upzonenj If you look at that New England Journal of Medicine article that came out last week, the antibody resonses they are seeing in the trial candidates strongly support the idea that the vaccine induces a good immune reponse. It should work. https://t.co/KEaLj6pKaM https://t.co/yqkobSDTqA
@Mike_Fabricant The @woodyjohnson4 And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity being measured at 90%! Very high. Maybe one dose will work for mass control & phase 3 trial soon! https://t.co/uaZPLoEoad https://t.co/wkNZHsEK8C
RT @waltercurioso: Ensayo fase 1-2a de vacuna Johnson & Johnson detectaron títulos anticuerpos neutralizantes SARS-CoV-2 en 90% o + el día…
RT @MonicaGandhi9: And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity bein…
@Arandomguy1235 @grparker22 @MadAngel07 @kylegriffin1 I didn’t make it through multivariable calculus just to fight with a dipstick like you. Moderna’s is 95% effective, Pfizer’s is at least 94.5%. Here is an article on it that you won’t understand because you choose to be stupid and hateful. https://t.co/i1j0xVD05D
@quig87 @NIHDirector @VP @moderna_tx @US_FDA @SteveFDA They haven't submitted b/c #FDA set the bar too high given the # of people dying every day. Johnson & Johnson published results showing it is safe & effective. The prior safety data on vaccines like J&J one is impecable. It's cruel not let people have it. https://t.co/zdeCeR7Z7E
@Laurie_Garrett @AstraZeneca No public safety data? None at all? I understand you want to see the P3 data (as do we all), but the words could have been chosen more precisely. https://t.co/S9P7AfV8p8
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/lVYrE8iX0h
RT @MonicaGandhi9: And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity bein…
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/zyoRW0StHu
RT @MonicaGandhi9: And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity bein…
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/5FOM97pcUt
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
イスラエルでPfizerのCOVID-19ワクチン1回目接種が感染の3割を防いだ https://t.co/B88Y1UU5vF ヤンセンファーマのワクチンも良好な結果が出ています https://t.co/7P0hoj69eC 良い結果が出てホッとしています
https://t.co/mRMai19fLq Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
J&Jのアデノウイルス26型ベクターワクチン（Ad26.COV2.S）か。 https://t.co/qOxrxlXanJ
RT @mannie_ub: https://t.co/Zl4QSkmbMP 承認は、3月にずれ込むと言われてましたが、少し前倒しです。AZのベクターワクチンより、良好な結果なのでしょうか？
RT @mannie_ub: https://t.co/Zl4QSkmbMP 承認は、3月にずれ込むと言われてましたが、少し前倒しです。AZのベクターワクチンより、良好な結果なのでしょうか？
https://t.co/Zl4QSkmbMP 承認は、3月にずれ込むと言われてましたが、少し前倒しです。AZのベクターワクチンより、良好な結果なのでしょうか？
Oooo Johnson & Johnson vaccine could be one of the game changers! One dose and it doesn't need refrigeration. Results of earlier trials in link https://t.co/8Ujt4jAPxJ https://t.co/7J15hdgUO2
RT @MonicaGandhi9: And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity bein…
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
RT @MonicaGandhi9: And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity bein…
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/nr1DfdaFW3 Free access article about the J & J vaccine.
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM @jsmadero @JRBneuropsiq @germanfajardo https://t.co/ZdgvVvgQrs
@TaisonBell Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/XRMAvoZLOF
RT @rousseau_phd: Interim Results of Phase 1–2a Trial of #Covid 19 @JNJNews Vaccine @NEJM | Safety & immunogenicity data are quite prom…
Interim Results of Phase 1–2a Trial of #Covid 19 @JNJNews Vaccine @NEJM | Safety & immunogenicity data are quite promising | Neutralizing antibody against wild-type virus found in more than 90% of participants after a single dose #science https://t.co/c5v9MOiPoe
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/ATS3Csqs9P
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
The immune response of those who got the vaccine in the J&J @JanssenUS Phase 1/2 trial is cause for optimism. Application for EUA may come in 4 to 6 weeks. Wonder what their stockpile is now and what their capabilities are. https://t.co/XJA6EtmEaf
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
RT @JamesEKHildreth: Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of partici…
Interim results from J&J phase 1/2 COVID19 adenovirus vaccine trial show very promising results. Up to 100% of participants made neutralizing antibody titers & most showed strong T cell responses. Data from phase 3 trial expected in next few weeks. https://t.co/D5thwkjB5U
RT @jimmytheplant: ORIGINAL ARTICLE Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine List of authors. Jerald Sadoff…
ORIGINAL ARTICLE Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine List of authors. Jerald Sadoff, M.D., Mathieu Le Gars, Ph.D., Georgi Shukarev, M.D., Dirk Heerwegh, Ph.D., et al. https://t.co/6VEOm7c33f
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/IVp62IxxdA
RT @MonicaGandhi9: And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity bein…
RT @MonicaGandhi9: And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity bein…
RT @MonicaGandhi9: And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity bein…
And here is the figure from the Johnson and Johnson vaccine phase I/II vaccine in NEJM - look at the immunogenicity being measured at 90%! Very high. Maybe one dose will work for mass control & phase 3 trial soon! https://t.co/en8Swcdm5E https://t.co/U9uEJxCgj6
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/K5PUZTXoDM
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/icmzqExfPR
RT @gkierzek: Et un vaccin de plus. 1 seule dose suffit ! Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. https://t.…
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/XbFkCOU9Nn
RT @gkierzek: Et un vaccin de plus. 1 seule dose suffit ! Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. https://t.…
RT @gkierzek: Et un vaccin de plus. 1 seule dose suffit ! Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. https://t.…
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM @JanssenUS #covid19vaccine @HSEQSALUDEMPRES @IDCBIS @DrVeller @SectorSalud @MinSaludCol https://t.co/ibL9ifWNc4
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM @JanssenUS #covid19vaccine https://t.co/mLUdEirjbh
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/YD6bbkvNzo
Promising. cDNA adenovirus vector #COVID19 Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/OV2d2c2dhO
RT @CarlosdelRio7: Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | The @NEJM publishes today the J&J #Covidvaccin…
RT @StefanoBerto83: The Johnson & Johnson vaccine seems good too. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine |…
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM (Janssen Vaccine) https://t.co/FrOLdlbHxF
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/csaisli3Ev
The Johnson & Johnson vaccine seems good too. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/Bp1xdyOSEM
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM looking good for our Dutch vaccine
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/XdwaAvTEl9 Another interesting approach obtaining high titers with the first dose. I look forward to seeing final results !
RT @BarouchLab: Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | @NEJM Exciting interim results, team
JANSSEN Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/4zlf7hNaPx
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/stWNun1mhZ
RT @minesoh: ジョンソンアンドジョンソンのベクターワクチンの治験 Phase1-2a の結果報告
ジョンソンアンドジョンソンのベクターワクチンの治験 Phase1-2a の結果報告
RT @the_paper_link: Trend up+1: **Sadoff J** et al (N Engl J Med) __Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine__…
Resultats preliminars fase 1-2 vacuna #COVID19 Janssen: eficàcia al voltant 90% amb una dosi? "Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine" | NEJM https://t.co/FQLU6umzoH
RT @carpe_diem0820: J&Jが開発する新型コロナワクチンの第Ⅰ/Ⅱ相臨床試験結果 中和抗体価は初回接種29日後に90％以上で検出 57日目に100％に到達 抗体力価は少なくとも71日目まで安定 2回目の接種で2.6～2.9倍力価が上昇 Interim Resu…
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/kA8htbJQPK
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/Vb2FWlvfoR
No 2 is: Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. https://t.co/vE44cfnTeU
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/9SMdqU7bnh
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/WyZzFjurNP
And third: Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. https://t.co/vE44cfnTeU
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/h6id0VU7Yw
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/cHwDYfJLrI
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine (Johnson & Johnson)
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S #Covid19 Vaccine | NEJM /// #clinicaltrial https://t.co/GHNkbP2r6V
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/3n3NEDXgmv
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM. Johnson and Johnson... los resultados. https://t.co/2BNS5zTH0K
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/c9XhHZIbuX
The article in New England Journal of Medicine, on J & J's "One-Shot" vaccine: "Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine" https://t.co/kgSlX9oVZC
Resultados provisionales de un ensayo de fase 1-2a de la vacuna Ad26.COV2.S Covid-19 | NEJM Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/Uj59IlBV3t
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/mVVnNN0leW
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/Th2xafDnoE
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/eWG1kSF0IV
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/BkDHtfmwxV
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/xkzpyrwzlh
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/SJQZYpacav
RT @Cormac_Sheridan: J&J due to report phase 3 data on its single-shot vaccine @ end of Jan. A +ve outcome would be a big boost to immuniza…
J&J due to report phase 3 data on its single-shot vaccine @ end of Jan. A +ve outcome would be a big boost to immunization efforts - but only if J&J irons out production issues. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/xtZp46e5ue
RT @MarcGozlan: Interim Results of a Phase 1–2a Trial of Ad26.COV2.S (Johnson & Johnson) Covid-19 Vaccine, after a single vaccination https…
RT @FerSuarezMD: J&J: Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/XZpFB1R4Yh
Interim results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine #covid19rftlks https://t.co/mJ3QN0L6V1
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM https://t.co/p3z1OkNwKy
J&J: Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://t.co/XZpFB1R4Yh
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM Sobre la vacuna de Johnson&Johnson y su respuesta inmune. https://t.co/LfRtEI3cWx
Our collaborator J. McElrath among authors of study of #covid19 vaccine prelim results https://t.co/s3uRFPmrqT @fredhutch @NEJM
Our story on Johnson & Johnson is updated with their paper that just came out in @NEJM that shows antibodies going strong 10 weeks after a single shot. https://www.nytimes.com/2021/01/13/health/covid-vaccine-johnson-johnson.html & paper: https://www.nejm.org/doi/10.1056/NEJMoa2034201